ENLIVEN THERAPEUTICS INC. - COMMON STOCK

Enliven Therapeutics Announces Positive Data Update from Phase 1 Clinical Trial of ELVN-001 in Chronic Myeloid Leukemia

28 9 2024 08:35:00 提供 Nasdaq GlobeNewswire

Enliven Therapeutics Announces Details Regarding the Presentation of Updated ELVN-001 Phase 1a Data at the ESH-iCMLf 26th Annual John Goldman Conference on CML

18 9 2024 15:05:07 提供 Nasdaq GlobeNewswire

Enliven Therapeutics Reports Second Quarter Financial Results and Provides a Business Update

13 8 2024 15:05:00 提供 Nasdaq GlobeNewswire

Enliven Therapeutics to Present at Two Upcoming Investor Conferences

29 5 2024 15:05:00 提供 Nasdaq GlobeNewswire

Enliven Therapeutics Reports First Quarter Financial Results and Provides a Business Update

14 5 2024 15:05:00 提供 Nasdaq GlobeNewswire

Enliven Therapeutics Announces Positive Proof of Concept Data from Phase 1 Clinical Trial of ELVN-001 in Chronic Myeloid Leukemia

11 4 2024 06:55:00 提供 Nasdaq GlobeNewswire

Enliven Therapeutics Appoints Dr. Lori Kunkel to Board of Directors

09 4 2024 15:05:00 提供 Nasdaq GlobeNewswire

Enliven Therapeutics to Share Initial Proof of Concept Data from Phase 1 Clinical Trial of ELVN-001 and Host Virtual Key Opinion Leader Event on April 11, 2024

28 3 2024 15:05:00 提供 Nasdaq GlobeNewswire